CreoSG Signs Material Transfer Agreement (MTA) with Alteogen

CreoSG announced on October 2 that it has signed a Material Transfer Agreement (MTA) with Alteogen.

CreoSG, through its subsidiary SmaGen Canada located at Western University in Canada, has acquired technology for an "innovative vaccine platform" and has registered the trademark for its evolved "attenuated recombinant VSV vector-based platform, SUV-MAP." Leveraging this, the company has achieved various milestones.

SUV-MAP is a next-generation vaccine platform that ensures both strong immunogenicity and safety. Utilizing this platform, CreoSG has established multiple vaccine pipelines, including those for COVID-19, Middle East Respiratory Syndrome (MERS), and Severe Fever with Thrombocytopenia Syndrome (SFTS). The safety of the platform has been demonstrated through non-clinical toxicity studies, and animal infection model tests have confirmed its excellent immune defense effects, further proving the versatility and competitiveness of SUV-MAP.

CreoSG is expanding the application of SUV-MAP beyond vaccines to serve as an immuno-oncology platform. In particular, the company is pursuing a universal platform strategy that targets both infectious diseases and cancer by developing oncolytic viruses that induce strong immune responses in the tumor microenvironment.

In this context, CreoSG is currently developing a next-generation immuno-oncology formulation by combining the rVSV platform with ALT-B4 technology through joint research with Alteogen. ALT-B4 is Alteogen's well-known hyaluronidase platform that converts intravenous (IV) formulations into subcutaneous (SC) formulations. Earlier this year, Alteogen secured a unique position in the oncology field by signing an exclusive agreement with the global pharmaceutical company MSD to convert the immuno-oncology drug Keytruda into an SC formulation.

A representative from CreoSG stated, "SUV-MAP is a universal platform with proven safety and efficacy, and expanding its use from vaccines to immuno-oncology drugs can significantly enhance the company's growth potential. With the signing of this Material Transfer Agreement (MTA) with Alteogen, we will actively engage in immuno-oncology research and development. At the same time, we will accelerate the development of immuno-oncology formulations utilizing ALT-B4 technology to secure unique competitiveness in the global healthcare market."